Long-acting GLP-1 drug TE-8105, developed by Taiwan biotech Immunwork, confirmed a five-day plasma half-life in first-in-human trials using a dual fatty acid bundle approach not used by any approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results